NASDAQ:CPRX

Catalyst Pharmaceuticals Stock Insider Trading

Healthcare > Biotechnology

Buy CPRX

*Your capital is at risk

$31.49

+0 (+0%)

At Close: Jul 31, 2026

Catalyst Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -100.00. In total, the insiders bought 0 and sold 16.46M CPRX shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-100.00
● Buy	0 shares
● Sell	16.46M shares
0% Buy Activity Weak Positive Correlation
Sell Signal High Confidence Jul 15, 2026 Analysis Breakdown: Strongly supported by a very low Insider Power Score of -100. Confidence increased due to high data reliability score of 100. Supported by overwhelming sell-side pressure (0% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
Jul 15, 2026 Sell	Options to purchase common stock D-Return	Sundaram Preethi Chief Strategy Officer	Officer	225 000 Value: $1.24M
Jul 15, 2026 Sell	Options to purchase common stock D-Return	Del Carmen Jeffrey Chief Commercial Officer	Officer	106 873 Value: $2.43M
Jul 15, 2026 Sell	Options to purchase common stock D-Return	Del Carmen Jeffrey Chief Commercial Officer	Officer	137 553 Value: $2.91M
Jul 15, 2026 Sell	Options to purchase common stock D-Return	Harper Molly Director	Director	29 524 Value: $417.8K
Jul 15, 2026 Sell	Common Stock, par value $0.001 per share D-Return	Harper Molly Director	Director	3 694 Value: $116.4K
Jul 15, 2026 Sell	Restricted Stock Units D-Return	Harper Molly Director	Director	5 468 Value: $0
Jul 15, 2026 Sell	Options to purchase common stock D-Return	Harper Molly Director	Director	18 115 Value: $412.5K
Jul 15, 2026 Sell	Options to purchase common stock D-Return	Harper Molly Director	Director	23 248 Value: $491.0K
Jul 15, 2026 Sell	Options to purchase common stock D-Return	Kalb Michael Wayne Chief Financial Officer	C-Suite Officer	257 214 Value: $4.32M
Jul 15, 2026 Sell	Common Stock, par value $0.001 per share D-Return	Kalb Michael Wayne Chief Financial Officer	C-Suite Officer	13 665 Value: $430.4K
Jul 15, 2026 Sell	Options to purchase common stock D-Return	Elsbernd Brian Chief Legal Officer	Officer	126 704 Value: $2.68M
Jul 15, 2026 Sell	Options to purchase common stock D-Return	Elsbernd Brian Chief Legal Officer	Officer	98 652 Value: $2.25M
Jul 15, 2026 Sell	Restricted Stock Units D-Return	Elsbernd Brian Chief Legal Officer	Officer	29 776 Value: $0
Jul 15, 2026 Sell	Options to purchase common stock D-Return	Curran Daniel J. Director	Director	40 000 Value: $844.8K
Jul 15, 2026 Sell	Options to purchase common stock D-Return	Curran Daniel J. Director	Director	18 115 Value: $412.5K
Jul 15, 2026 Sell	Restricted Stock Units D-Return	Curran Daniel J. Director	Director	5 468 Value: $0
Jul 15, 2026 Sell	Options to purchase common stock D-Return	Tierney David S Director	Director	23 248 Value: $491.0K
Jul 15, 2026 Sell	Options to purchase common stock D-Return	Tierney David S Director	Director	18 115 Value: $412.5K
Jul 15, 2026 Sell	Restricted Stock Units D-Return	Tierney David S Director	Director	5 468 Value: $0
Jul 15, 2026 Sell	Common Stock, par value $0.001 per share D-Return	Miller Steve Chief Op. & Scientific Officer	Officer	1 093 803 Value: $34.5M
Jul 15, 2026 Sell	Options to purchase common stock D-Return	Miller Steve Chief Op. & Scientific Officer	Officer	180 000 Value: $835.2K
Jul 15, 2026 Sell	Options to purchase common stock D-Return	Miller Steve Chief Op. & Scientific Officer	Officer	275 000 Value: $940.5K
Jul 15, 2026 Sell	Options to purchase common stock D-Return	Miller Steve Chief Op. & Scientific Officer	Officer	185 000 Value: $1.31M
Jul 15, 2026 Sell	Options to purchase common stock D-Return	Thompson Tamar Director	Director	29 524 Value: $417.8K
Jul 15, 2026 Sell	Options to purchase common stock D-Return	Thompson Tamar Director	Director	23 248 Value: $491.0K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT CATALYST PHARMACEUTICALS

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develop...

Read Full Profile Here